Table 1.
Clinicopathologic variables for patient cohort.
| Responders (n=40) | Non-Responders (n=22) | p-value | ||
|---|---|---|---|---|
| Age (range 17.4–85.5 yr) | Mean (SD) | 53.1 (15.0) | 63.3 (12.7) | 0.008 |
| Treatment regimes | Anthra-HDAC | 33 (53.2%) | 15 (24.2%) | 0.0001 |
| Flu-HDAC | 7 (11.3%) | 0 (0.0%) | ||
| HDAC-plus non Anthra | 0 (0.0%) | 7 (11.3%) | ||
| Gender | Male | 16 (25.8%) | 10 (16.1%) | 0.68 |
| Female | 24 (38.7%) | 12 (19.4%) | ||
| FAB (French-American- British classification) | M0 | 0 (0.0%) | 2 (3.3%) | 0.36 |
| M1 | 7 (11.5%) | 2 (3.3%) | ||
| M2 | 9 (14.8%) | 9 (14.8%) | ||
| M4 | 10 (16.4%) | 6 (9.8%) | ||
| M5 | 11 (18.0%) | 2 (3.3%) | ||
| M7 | 1 (1.6%) | 0 (0.0%) | ||
| RAEBT | 1 (1.6%) | 1 (1.6%) | ||
| Cyto-genetics | Favorable | 4 (6.5%) | 0 (0.0%) | 0.003 |
| Intermediate | 26 (41.9%) | 8 (12.9%) | ||
| Unfavorable | 9 (14.5%) | 14 (22.6%) | ||
| NA | 1 (1.6%) | 0 (0.0%) | ||
| Performance Status | 0 | 4 (6.4%) | 7 (11.3%) | 0.18 |
| 1 | 22 (35.5%) | 12 (19.4%) | ||
| 2+ | 14 (22.6%) | 3 (4.8%) | ||
| NPM1 | Mutation | 6 (9.7%) | 4 (6.5%) | 0.47 |
| Wild type | 11 (17.7%) | 14 (22.6%) | ||
| NA | 23 (37.1%) | 4 (6.5%) | ||
| FLT3 ITD | Positive | 11 (17.7%) | 6 (9.7%) | 0.92 |
| Negative | 24 (38.7%) | 14 (22.6%) | ||
| NA | 5 (8.1%) | 2 (3.2%) | ||
| FLT3 D835 | Positive | 3 (4.8%) | 1 (1.6%) | 0.89 |
| Negative | 33 (53.2%) | 19 (30.7%) | ||
| NA | 4 (6.5%) | 2 (3.2%) | ||
| Ras mutation | Positive | 4 (6.5%) | 4 (6.5%) | 0.47 |
| Negative | 19 (30.6%) | 12 (19.3%) | ||
| NA | 17 (27.4%) | 6 (9.7%) |
Comparisons between responders and non-responders on patient characteristics are made by Chi-square tests (Fisher’s exact tests if sample size for any cell of table is less than 5) for categorical variables, and Mann-Whitney tests for continuous variables. Of these variables only age, cyto-genetic status, and treatment were statistically significant for responders (CR) versus non-responders (NR). p value<0.01.